TrumpRx: 92 Drug Deals Cover <12% of Brand-Name Portfolio

For healthcare providers and patients, the promise of direct government-brokered drug discounts was a potential game-changer in the fight against high prescription costs. But an NPR analysis of the TrumpRx website reveals that only 92 medications are currently listed, representing fewer than 12% of the participating companies’ brand-name portfolios. The limited catalog, which omits many critical therapies, raises urgent questions about whether executive-driven market interventions can truly enhance patient access to affordable medicines.

President Trump’s flagship drug pricing initiative, TrumpRx, was unveiled in February 2026 as a government-run online portal designed to provide direct-to-consumer discounts on brand-name prescription drugs. The website was heralded as a 'supermarket' for affordable medications, part of a broader executive order from May 2025 that aimed to bring U.S. drug prices in line with those paid in other wealthy nations. However, nearly six months after its launch, an NPR analysis of FDA drug databases published on July 16, 2026, reveals that TrumpRx is more akin to a boutique than a supermarket. The site features only 92 deals, a figure that represents fewer than 12% of the over 800 brand-name drugs manufactured by the 17 pharmaceutical companies that struck agreements with the Trump administration. The shortfall is stark: entire therapeutic categories—including treatments for inflammatory conditions, HIV, and cancer—are entirely absent from the platform. As Dr. Ben Rome, health policy researcher at Brigham and Women’s Hospital, noted, 'most of these companies are doing this for a small number of products and in a limited setting.'

“

But an NPR analysis of the TrumpRx website reveals that only 92 medications are currently listed, representing fewer than 12% of the participating companies’ brand-name portfolios.

The gap between rhetoric and reality stems from the negotiation framework. The administration’s approach relied on voluntary cooperation after sending threatening letters in the summer of 2025, demanding lower prices and warning of tariff repercussions from a parallel investigation into pharmaceutical imports. The tactic, while securing high-profile announcements from companies like Eli Lilly and Novo Nordisk—both of which had already begun direct-to-consumer pricing models—failed to compel broad-based participation. Instead, drugmakers appear to have offered a handful of products, often those with upcoming patent expirations or niche indications, while shielding their blockbuster drugs from the discount portal. For instance, while Lilly agreed to list some products, its top-selling diabetes and obesity medications are not among the 92 deals. This selective engagement preserves the companies’ ability to maximize revenue from high-demand drugs through traditional insurance and pharmacy benefit manager channels, where opaque rebates and list prices remain elevated.

The implications for patients are significant. The promise of TrumpRx was to create a parallel market that bypasses middlemen and delivers savings directly to consumers, mirroring the model pioneered by Mark Cuban Cost Plus Drug Company and, to a lesser extent, direct-to-consumer platforms from LillyDirect and NovoCare. But with only 92 products, the program fails to offer a comprehensive solution. Patients requiring specialty medications for chronic, life-threatening, or rare conditions are left with no alternative through this channel. Moreover, the website’s branding as a Trump administration achievement risks conflating political messaging with meaningful healthcare cost reduction, potentially undermining public trust in future price-transparency efforts.